Developer docs
API playgroundTry for free, no card

Search company profiles

Aulos Bioscience

Full company profile

uuid0000pg8

Namestring
Aulos Bioscience
Legal namestring
Aulos Bioscience Inc.
Websiteurl
aulosbio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Aulos Bioscience is a privately held, clinical-stage immuno-oncology company developing imneskibart (AU-007), a human IgG1 monoclonal antibody computationally designed by co-founder Biolojic Design to selectively bind the CD25-binding portion of interleukin-2 (IL-2). By occupying this epitope, imneskibart redirects endogenous IL-2 toward effector T cells and NK cells while preventing IL-2 from engaging trimeric receptors on regulatory T cells, the vasculature, and pulmonary endothelium — thereby avoiding the vascular leak syndrome and pulmonary edema that have historically limited high-dose IL-2 therapy. The drug is administered as an outpatient regimen with a half-life exceeding 19 days, enabling bi-weekly dosing.

The company is conducting a Phase 1/2 clinical trial (NCT05267626) at sites in the United States and Australia, evaluating imneskibart as monotherapy and in combination with low-dose subcutaneous aldesleukin, nivolumab, and avelumab across solid tumor indications including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, bladder cancer, and head and neck cancer. Phase 2 data reported at the 2026 ASCO Annual Meeting showed a 33% objective response rate and 67% disease control rate in doublet checkpoint inhibitor-refractory metastatic melanoma. A clinical trial collaboration and supply agreement with Merck KGaA provides avelumab (Bavencio) for the NSCLC combination cohort.

Aulos was launched in January 2021 as a joint venture between Apple Tree Partners (ATP), which provided a $40 million Series A and a $20 million extension in August 2023 (totaling $60 million in funding), and Biolojic Design, which contributed the AI antibody design platform. The company is headquartered in Larkspur, California, operates with 1–10 employees, and is wholly backed by ATP. Its business model is pre-revenue and clinical-development oriented, with planned future revenue generation through either out-licensing transactions with pharmaceutical partners or an independent commercial launch contingent on registrational trial success.

Short descriptiontext

Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), an AI-designed monoclonal antibody that redirects IL-2 toward anti-tumor immune activation while avoiding Treg expansion and IL-2 toxicities, currently in Phase 2 trials for solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLarkspur, United States
HQ citystring
Larkspur
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapeutics, monoclonal antibody development, IL-2 cancer therapy, clinical-stage biotechnology, solid tumor treatment
Industry2 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Immuno-oncology therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company developing IL-2 therapeutics for solid tumor cancers. Revenue will be generated through future product sales upon regulatory approval.

businesswire.com
2Pharmaceutical Partnerships
TypeLicensing Royalties
Description

Strategic collaborations and licensing agreements with pharmaceutical companies for development and commercialization rights. The company has clinical trial collaboration and supply agreements with Merck KGaA.

aulosbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), a computationally designed human IgG1 monoclonal antibody that binds to the CD25-binding portion of interleukin-2 (IL-2). It redirects IL-2 activity toward immune activation (effector T cells and NK cells) and away from immune suppression (regulatory T cells), while avoiding the vascular leak syndrome and pulmonary edema associated with conventional IL-2 therapy. The company is advancing this single lead candidate through Phase 1/2 clinical trials for solid tumor cancers including melanoma and non-small cell lung cancer (NSCLC).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 33% objective response rate (ORR) and 67% disease control rate in doublet CPI-refractory metastatic melanoma patients receiving triplet regimen (imneskibart + low-dose aldesleukin + nivolumab)
+5 more records
Product overview1 text field

Aulos Bioscience is developing a single core product candidate, imneskibart (AU-007), an IL-2 redirecting antibody therapeutic for solid tumor cancers. The company was founded by Biolojic Design and Apple Tree Partners to develop this AI-designed monoclonal antibody through clinical trials. The product is currently in Phase 1/2 clinical development with multiple expansion cohorts studying the antibody alone and in combination with aldesleukin, nivolumab, and avelumab for treatment of melanoma, NSCLC, and renal cell carcinoma.

Product and service1 record
1Imneskibart (AU-007)
CategoryImmuno-oncology monoclonal antibody therapeutic
Description

A human IgG1 monoclonal antibody designed using artificial intelligence by Biolojic Design that is highly selective to the CD25-binding portion of interleukin-2 (IL-2). It redirects IL-2 to reinforce anti-tumor immune effects by preventing IL-2 from binding to trimeric receptors on regulatory T cells while allowing IL-2 to bind and expand effector T cells and NK cells. Being developed for treatment of solid tumor cancers including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, both as monotherapy and in combination with aldesleukin, nivolumab, and avelumab.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Merck KGaA, Darmstadt, Germany (Ares Trading S.A.)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-27
Description

Clinical trial collaboration and supply agreement for use of avelumab (anti-PD-L1 antibody with Fc effector function) in combination with AU-007 and low-dose subcutaneous aldesleukin in a Phase 2 cohort for second-line treatment of PD-L1+ non-small cell lung cancer. Avelumab is approved for multiple tumor types and is the only approved PD-L1/PD-1 antibody with Fc effector function.

aulosbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-08
Description

Co-founding strategic partner and technology provider. Biolojic Design, founded by Yanay Ofran, provides the AI/computationally-designed antibody platform that designed imneskibart (AU-007). Yanay Ofran serves as co-founder and chief scientific officer of Aulos. The company was founded by Biolojic Design and ATP.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cooperation agreement with Teva for research and development activities. Teva is a multinational pharmaceutical company.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cooperation agreement with Nektar Therapeutics for research and development activities. Nektar is a biopharmaceutical company.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in the IL-2 immuno-oncology space. Nektar developed bempegaldesleukin, a PEGylated IL-2 agonist, and is already an Aulos research partner, providing highly relevant comparability on mechanism and clinical development challenges.

TypeDirect peer
Description

Clinical-stage biotech developing conditionally activated IL-2 and IL-12 prodrugs (PREDATOR platform) for solid tumors. Directly comparable as a smaller, IL-2-focused immuno-oncology competitor with tumor microenvironment-selective approaches.

TypeDirect peer
Description

Develops engineered IL-2 and IL-4 'super-kines' for immuno-oncology. Comparable as a clinical-stage, IL-2 pathway-focused biotech pursuing differentiated cytokine-based mechanisms in solid tumors.

TypeDirect peer
Description

Clinical-stage biotech developing tumor-activated IL-2 and IL-15 molecules and checkpoint inhibitors. Closely comparable to Aulos in stage, size, and focus on localized IL-2 immune activation in solid tumors.

TypeEmerging player
Description

Clinical-stage oncology company with a pipeline spanning EGFR, CLDN18.2, and immune-engaging assets. Comparable as a similarly-sized immuno-oncology biotech with a multi-asset portfolio strategy.

TypeBroad incumbent
Description

Global pharmaceutical company with deep immuno-oncology portfolio and historical IL-2 program work. Comparable as a broad incumbent whose checkpoint inhibitor (via Bavencio/avelumab partnership) and oncology expertise frame AU-007's commercial landscape.

TypeBroad incumbent
Description

Global pharma with leading oncology franchise including checkpoint inhibitors (Tecentriq) and IL-2 pathway research. Comparable as a broad incumbent defining the immuno-oncology competitive and partnership landscape.

8Bristol-Myers Squibb
TypeBroad incumbent
Description

Major immuno-oncology incumbent with Opdivo (nivolumab) and Yervoy, the backbone CPI agents in Aulos's combination regimens. Comparable as the established leader in CPI-refractory melanoma treatment that AU-007 is positioning to follow.

TypeBroad incumbent
Description

Existing Aulos partner supplying avelumab (Bavencio) for NSCLC combination trials. Comparable as a broad oncology incumbent and validation partner whose commercial reach could enable global launch.

TypeEmerging player
Description

AI-driven predictive computational biology company developing immuno-oncology targets. Comparable as a peer leveraging computational platforms to discover novel immuno-oncology targets, though at an earlier and broader discovery stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aulos Bioscience

Immuno-oncology therapeuticsaulosbio.com

Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), an AI-designed monoclonal antibody that redirects IL-2 toward anti-tumor immune activation while avoiding Treg expansion and IL-2 toxicities, currently in Phase 2 trials for solid tumors.

What Aulos Bioscience does

Aulos Bioscience is a privately held, clinical-stage immuno-oncology company developing imneskibart (AU-007), a human IgG1 monoclonal antibody computationally designed by co-founder Biolojic Design to selectively bind the CD25-binding portion of interleukin-2 (IL-2). By occupying this epitope, imneskibart redirects endogenous IL-2 toward effector T cells and NK cells while preventing IL-2 from engaging trimeric receptors on regulatory T cells, the vasculature, and pulmonary endothelium — thereby avoiding the vascular leak syndrome and pulmonary edema that have historically limited high-dose IL-2 therapy. The drug is administered as an outpatient regimen with a half-life exceeding 19 days, enabling bi-weekly dosing.

The company is conducting a Phase 1/2 clinical trial (NCT05267626) at sites in the United States and Australia, evaluating imneskibart as monotherapy and in combination with low-dose subcutaneous aldesleukin, nivolumab, and avelumab across solid tumor indications including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, bladder cancer, and head and neck cancer. Phase 2 data reported at the 2026 ASCO Annual Meeting showed a 33% objective response rate and 67% disease control rate in doublet checkpoint inhibitor-refractory metastatic melanoma. A clinical trial collaboration and supply agreement with Merck KGaA provides avelumab (Bavencio) for the NSCLC combination cohort.

Aulos was launched in January 2021 as a joint venture between Apple Tree Partners (ATP), which provided a $40 million Series A and a $20 million extension in August 2023 (totaling $60 million in funding), and Biolojic Design, which contributed the AI antibody design platform. The company is headquartered in Larkspur, California, operates with 1–10 employees, and is wholly backed by ATP. Its business model is pre-revenue and clinical-development oriented, with planned future revenue generation through either out-licensing transactions with pharmaceutical partners or an independent commercial launch contingent on registrational trial success.

Aulos Bioscience firmographics

Firmographics
Name
Aulos Bioscience
Legal name
Aulos Bioscience Inc.
Website
https://aulosbio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), an AI-designed monoclonal antibody that redirects IL-2 toward anti-tumor immune activation while avoiding Treg expansion and IL-2 toxicities, currently in Phase 2 trials for solid tumors.
Ownership category
akta.pro rank

Aulos Bioscience industry classification

Industry
Product category
Immuno-oncology therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Immuno-oncology therapeutics
  • Monoclonal antibody development
  • IL-2 cancer therapy
  • Clinical-stage biotechnology
  • Solid tumor treatment

Where Aulos Bioscience is headquartered

Location

Headquarters

HQ city
Larkspur
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aulos Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biotech company developing IL-2 therapeutics for solid tumor cancers. Revenue will be generated through future product sales upon regulatory approval.
  2. Pharmaceutical Partnerships: Strategic collaborations and licensing agreements with pharmaceutical companies for development and commercialization rights. The company has clinical trial collaboration and supply agreements with Merck KGaA.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Aulos Bioscience product offering

Product offering

Core offering

Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), a computationally designed human IgG1 monoclonal antibody that binds to the CD25-binding portion of interleukin-2 (IL-2). It redirects IL-2 activity toward immune activation (effector T cells and NK cells) and away from immune suppression (regulatory T cells), while avoiding the vascular leak syndrome and pulmonary edema associated with conventional IL-2 therapy. The company is advancing this single lead candidate through Phase 1/2 clinical trials for solid tumor cancers including melanoma and non-small cell lung cancer (NSCLC).

Product overview

Aulos Bioscience is developing a single core product candidate, imneskibart (AU-007), an IL-2 redirecting antibody therapeutic for solid tumor cancers. The company was founded by Biolojic Design and Apple Tree Partners to develop this AI-designed monoclonal antibody through clinical trials. The product is currently in Phase 1/2 clinical development with multiple expansion cohorts studying the antibody alone and in combination with aldesleukin, nivolumab, and avelumab for treatment of melanoma, NSCLC, and renal cell carcinoma.

Differentiator

Problem solved

Functional benefit

Products and services

  • Imneskibart (AU-007) A human IgG1 monoclonal antibody designed using artificial intelligence by Biolojic Design that is highly selective to the CD25-binding portion of interleukin-2 (IL-2). It redirects IL-2 to reinforce anti-tumor immune effects by preventing IL-2 from binding to trimeric receptors on regulatory T cells while allowing IL-2 to bind and expand effector T cells and NK cells. Being developed for treatment of solid tumor cancers including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, both as monotherapy and in combination with aldesleukin, nivolumab, and avelumab.

Quantifiable outcome

  • 33% objective response rate (ORR) and 67% disease control rate in doublet CPI-refractory metastatic melanoma patients receiving triplet regimen (imneskibart + low-dose aldesleukin + nivolumab)
  • +5 more outcomes

Companies that use Aulos Bioscience

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Aulos Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Aulos Bioscience partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Merck KGaA, Darmstadt, Germany (Ares Trading S.A.)coreStrategic or Co-development Partner · 27 November 2024Clinical trial collaboration and supply agreement for use of avelumab (anti-PD-L1 antibody with Fc effector function) in combination with AU-007 and low-dose subcutaneous aldesleukin in a Phase 2 cohort for second-line treatment of PD-L1+ non-small cell lung cancer. Avelumab is approved for multiple tumor types and is the only approved PD-L1/PD-1 antibody with Fc effector function.
  • Biolojic DesigncoreStrategic or Co-development Partner · 8 January 2021Co-founding strategic partner and technology provider. Biolojic Design, founded by Yanay Ofran, provides the AI/computationally-designed antibody platform that designed imneskibart (AU-007). Yanay Ofran serves as co-founder and chief scientific officer of Aulos. The company was founded by Biolojic Design and ATP.
  • TevaminorStrategic or Co-development PartnerCooperation agreement with Teva for research and development activities. Teva is a multinational pharmaceutical company.
  • Nektar TherapeuticsminorStrategic or Co-development PartnerCooperation agreement with Nektar Therapeutics for research and development activities. Nektar is a biopharmaceutical company.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Aulos Bioscience competitors and assessment

Company assessment

Direct peers

  • Nektar Therapeutics: Direct competitor in the IL-2 immuno-oncology space. Nektar developed bempegaldesleukin, a PEGylated IL-2 agonist, and is already an Aulos research partner, providing highly relevant comparability on mechanism and clinical development challenges.
  • Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated IL-2 and IL-12 prodrugs (PREDATOR platform) for solid tumors. Directly comparable as a smaller, IL-2-focused immuno-oncology competitor with tumor microenvironment-selective approaches.
  • Medicenna Therapeutics: Develops engineered IL-2 and IL-4 'super-kines' for immuno-oncology. Comparable as a clinical-stage, IL-2 pathway-focused biotech pursuing differentiated cytokine-based mechanisms in solid tumors.
  • Xilio Therapeutics: Clinical-stage biotech developing tumor-activated IL-2 and IL-15 molecules and checkpoint inhibitors. Closely comparable to Aulos in stage, size, and focus on localized IL-2 immune activation in solid tumors.

Emerging players

  • Cullinan Oncology: Clinical-stage oncology company with a pipeline spanning EGFR, CLDN18.2, and immune-engaging assets. Comparable as a similarly-sized immuno-oncology biotech with a multi-asset portfolio strategy.
  • Compugen: AI-driven predictive computational biology company developing immuno-oncology targets. Comparable as a peer leveraging computational platforms to discover novel immuno-oncology targets, though at an earlier and broader discovery stage.

Broad incumbents

  • Pfizer: Global pharmaceutical company with deep immuno-oncology portfolio and historical IL-2 program work. Comparable as a broad incumbent whose checkpoint inhibitor (via Bavencio/avelumab partnership) and oncology expertise frame AU-007's commercial landscape.
  • Roche: Global pharma with leading oncology franchise including checkpoint inhibitors (Tecentriq) and IL-2 pathway research. Comparable as a broad incumbent defining the immuno-oncology competitive and partnership landscape.
  • Bristol-Myers Squibb: Major immuno-oncology incumbent with Opdivo (nivolumab) and Yervoy, the backbone CPI agents in Aulos's combination regimens. Comparable as the established leader in CPI-refractory melanoma treatment that AU-007 is positioning to follow.
  • Merck KGaA: Existing Aulos partner supplying avelumab (Bavencio) for NSCLC combination trials. Comparable as a broad oncology incumbent and validation partner whose commercial reach could enable global launch.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Aulos Bioscience social profiles

Digital presence

Aulos Bioscience compliance and trust

Trust signal

Compliance1 record

Aulos Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aulos Bioscience leadership team

Management profile

Number of profiles

Profiles10 records

Aulos Bioscience funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aulos Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aulos Bioscience

What does Aulos Bioscience do?

Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), a computationally designed human IgG1 monoclonal antibody that binds to the CD25-binding portion of interleukin-2 (IL-2). It redirects IL-2 activity toward immune activation (effector T cells and NK cells) and away from immune suppression (regulatory T cells), while avoiding the vascular leak syndrome and pulmonary edema associated with conventional IL-2 therapy. The company is advancing this single lead candidate through Phase 1/2 clinical trials for solid tumor cancers including melanoma and non-small cell lung cancer (NSCLC).

Is Aulos Bioscience a public or private company?

Aulos Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aulos Bioscience founded?

Aulos Bioscience was founded in 2021. It employs 11 to 50 people.

Where is Aulos Bioscience based?

Aulos Bioscience is headquartered in Larkspur, United States, in the North America region.

How does Aulos Bioscience make money?

Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are pharmaceutical Partnerships.

Who are Aulos Bioscience's main competitors?

Direct peers on record are Nektar Therapeutics, Werewolf Therapeutics, Medicenna Therapeutics and Xilio Therapeutics. Emerging players are Cullinan Oncology and Compugen. Broad incumbents are Pfizer, Roche, Bristol-Myers Squibb and Merck KGaA.

Does Aulos Bioscience have an API?

No public API is recorded for Aulos Bioscience.

What industry is Aulos Bioscience in?

Aulos Bioscience's product category is Immuno-oncology therapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAulos Bioscience’s Imneskibart Demonstrates Outstanding Phase 2 Activity in Checkpoint Inhibitor-Refractory Melanoma and Lung Cancer, Comparing Favorably With Historical Treatment BenchmarksAulos Bioscience reported Phase 2 data for imneskibart in checkpoint inhibitor-refractory melanoma and lung cancer, showing median PFS of 9.1 months and 28% ORR in melanoma, and 5.8 months and 21% ORR in lung adenocarcinoma. The results compare favorably with historical benchmarks, and the company plans to advance into randomized trials.FinancialContent Business PageAulos Bioscience’s Imneskibart Demonstrates Outstanding Phase 2 Activity in Checkpoint Inhibitor-Refractory Melanoma and Lung Cancer, Comparing Favorably With Historical Treatment BenchmarksAulos Bioscience reported Phase 2 data for imneskibart in checkpoint inhibitor-refractory melanoma and lung cancer, showing median PFS of 9.1 months and 28% ORR in melanoma, and 5.8 months and 21% ORR in NSCLC. The results compare favorably with historical benchmarks, and the company plans to advance into randomized trials.Business Wire BlogAulos Bioscience’s Imneskibart With Avelumab Delivers Exceptional Progression-Free Survival in Checkpoint Inhibitor-Refractory Adenocarcinoma Non-Small Cell Lung CancerAulos Bioscience presented Phase 2 data for imneskibart with avelumab in checkpoint inhibitor-refractory adenocarcinoma NSCLC, showing median progression-free survival of 5.8 months and a 21% confirmed objective response rate. The 86% disease control rate and tolerable safety profile support advancing the triplet into randomized trials.FinancialContent Business PageAulos Bioscience’s Imneskibart With Avelumab Delivers Exceptional Progression-Free Survival in Checkpoint Inhibitor-Refractory Adenocarcinoma Non-Small Cell Lung CancerAulos Bioscience presented Phase 2 data for imneskibart with avelumab in checkpoint inhibitor-refractory adenocarcinoma NSCLC at ESMO 2026. Median progression-free survival was 5.8 months, confirmed objective response rate 21%, and disease control rate 86% in 14 evaluable patients. The company plans to advance the regimen into randomized clinical trial evaluation.FinancialContent Business PageAulos Bioscience to Present Phase 2 Data for Imneskibart With Avelumab in Adenocarcinoma Non-Small Cell Lung Cancer at ESMO Congress 2026Aulos Bioscience will present Phase 2 data for imneskibart with avelumab in checkpoint inhibitor-refractory adenocarcinoma NSCLC at ESMO Congress 2026 in Madrid. The poster presentation is scheduled for October 26, 2026, with the abstract published online on October 19.Business Wire BlogAulos Bioscience to Present Phase 2 Data for Imneskibart With Avelumab in Adenocarcinoma Non-Small Cell Lung Cancer at ESMO Congress 2026Aulos Bioscience will present Phase 2 data for imneskibart with avelumab in checkpoint inhibitor-refractory adenocarcinoma NSCLC at ESMO Congress 2026 in Madrid. The poster presentation is scheduled for October 26, 2026, and the abstract will be published online on October 19, 2026.FinancialContent Business PageAulos Bioscience Announces Presentations of Promising Phase 1/2 Data for Imneskibart With Checkpoint Inhibitors in Non-Small Cell Lung Cancer and Melanoma at SITC 2026 Annual MeetingAulos Bioscience announced two presentations of Phase 1/2 data for its antibody imneskibart at the SITC 2026 Annual Meeting. One presentation covers Phase 2 results with avelumab in checkpoint inhibitor-refractory NSCLC, and the other covers Phase 1/2 data with nivolumab in doublet CPI-refractory melanoma.Business Wire BlogAulos Bioscience Announces Presentations of Promising Phase 1/2 Data for Imneskibart With Checkpoint Inhibitors in Non-Small Cell Lung Cancer and Melanoma at SITC 2026 Annual MeetingAulos Bioscience announced two poster presentations at SITC 2026 for its Phase 1/2 study of imneskibart. One presentation covers Phase 2 data with avelumab in CPI-refractory NSCLC, and the other covers Phase 1/2 data with nivolumab in doublet CPI-refractory melanoma. The presentations are scheduled for November 6, 2026.CTech"In biotechnology, it's billions of dollars, or zero"Ukko Laboratories, founded by Prof. Yanay Ofran, has begun Phase 1 human clinical trials in Australia and New Zealand for Ukko18, an RNA-based therapy designed to eliminate or significantly reduce peanut allergies, with the first participant — a teenager from New Zealand — receiving the injection approximately three weeks ago. The therapy, developed over eight years using AI, represents the world's first RNA-based treatment for food allergies and the first AI-designed molecule in its field to enter human trials, requiring only two to three injections rather than the daily dosing of current treatments. Ofran's other company, Biolojic Design/Aulos Bioscience, has an AI-designed cancer immunotherapy drug already in Phase 2 human trials, and both companies have cooperation agreements with pharmaceutical giants Merck, Teva, and Nektar Therapeutics, having raised over $200 million for research combined.BioSpaceAulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual MeetingAulos Bioscience reported positive Phase 2 data for imneskibart in doublet checkpoint inhibitor-refractory metastatic melanoma, presenting at ASCO 2026. The imneskibart triplet regimen achieved a 33% objective response rate and 67% disease control rate across 83 patients, with no treatment discontinuations due to drug-related adverse events. Enrollment continues in melanoma and PD-L1+ NSCLC cohorts.